3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 95.0%, 25g

Olmutinib, 90%, 5mg

3-(Bromomethyl)-3-ethyloxetane, 98%, 5g

6-Chloro-5-nitropyrimidin-4-amine, 97.0%, 5g

METHYL 2-FLUORO-5-METHOXYBENZOATE, 95.0%, 250mg

Silicon AAS standard solution, ROTI®Star, 1000 mg/l Si , density (D) 1.002 g/cm³

2-(3,4-dihydro-2(1H)-isoquinolinyl)propanoic acid hydrochloride hydrate, 95.0%, 1g

3-(2-(2-(2-Bromoethoxy)ethoxy)ethoxy)propanoic acid, 97.0%, 250mg

amino(3-hydroxyphenyl)acetic acid hydrochloride, 95.0%, 5g

2-Amino-4-(3,4-difluorophenyl)thiazole, 98.0%, 500g

tert-Butyl 5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate, 95.0%, 250mg

2-(2-Methyl-1,3-dioxolan-2-yl)ethanamine, 95.0%, 1g

5-Bromo-1-cyclobutyl-1,2-dihydropyrimidin-2-one, >95%, 1g